Abstract 23P
Background
Lung cancer is a leading cause of mortality globally, particularly the subtype called lung adenocarcinoma (LUAD). Current treatments have limited success, emphasizing the need for better therapies. Heparan sulfate proteoglycans (HSPGs) and heparanase (Hpse) play important roles in cancer progression, including LUAD, but their exact functions are not fully understood. Our study aims to explore Hpse's relevance in LUAD progression and its effects on tumor cells.
Methods
We introduced shRNAs by lentiviral transfections against heparanase into a murine and a human cell line. We performed intravenous and orthotopic injections to assess the effects of our genetic perturbations on tumor growth, survival, and the tumor immune microenvironment.
Results
The study investigated the correlation between heparanase mRNA expression and overall survival in LUAD patients. Using the PRECOGG database and the Cancer Genome Atlas, we found that elevated HPSE expression correlated with poor overall survival in LUAD patients. Additionally, in vitro experiments demonstrated that heparanase promoted migration and invasion of lung cancer cells, suggesting its role in metastasis. Moreover, in vivo studies using mouse models showed that Hpse knockdown reduced tumor growth and metastasis and increased the survival of mice. Spectral flow cytometry analysis revealed many changes in the immune microenvironment between tumors with high and low Hpse expression, with significant alterations in myeloid and lymphoid cell populations. Notably, in Hpsel-low tumors, alveolar macrophages were more abundant. Surprisingly, these macrophages displayed an anti-tumorigenic phenotype characterized based on single-cell sequencing performed on leukocytes.
Conclusions
To conclude, our findings support our clinical analysis revealing that heparanase should be investigated further as a therapeutic target for patients with LUAD. More effort should be put towards inhibitors and trials should focus on this patient population that is in dire need of novel treatment options.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
CIHR.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract